Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-46,700
Closed -$14.3M 2817
2015
Q4
$14.3M Buy
46,700
+3,300
+8% +$948K 0.24% 40
2015
Q3
$12.7M Buy
43,400
+29,100
+203% +$9.61M 0.21% 43
2015
Q2
$5.78M Buy
14,300
+3,800
+36% +$1.53M 0.1% 105
2015
Q1
$4.43M Sell
10,500
-12,000
-53% -$4.73M 0.09% 140
2014
Q4
$7.64M Buy
22,500
+12,200
+118% +$3.95M 0.13% 73
2014
Q3
$3.41M Sell
10,300
-4,300
-29% -$1.42M 0.07% 239
2014
Q2
$4.6M Sell
14,600
-46,300
-76% -$13.9M 0.07% 200
2014
Q1
$18.6M Buy
60,900
+37,400
+159% +$11.9M 0.23% 55
2013
Q4
$6.57M Sell
23,500
-10,600
-31% -$2.74M 0.07% 160
2013
Q3
$8.21M Buy
+34,100
New +$7.63M 0.1% 123

Other funds holding BIIB

Virtu KCG Holdings's BIIB Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Biogen (BIIB) stake by 48% in Q2 2017, selling an estimated $1.69M and leaving 7,022 shares worth $1.91M. The position accounts for 0.05% of the portfolio, ranked #268.

Virtu KCG Holdings first reported a position in BIIB in Q3 2013 and has held it in 13 quarters since. The position peaked at $14.2M in Q1 2015. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Virtu KCG Holdings held 7,022 shares of Biogen worth $1.91M as of Q2 2017.
  • Virtu KCG Holdings sold 6,404 Biogen shares in Q2 2017, an estimated $1.69M.
  • Biogen made up 0.05% of Virtu KCG Holdings's portfolio in Q2 2017, its #268 holding.
  • Virtu KCG Holdings first reported a position in Biogen in Q3 2013 and has held it in 13 quarters since.
  • Virtu KCG Holdings's Biogen position peaked at $14.2M in Q1 2015.
  • 992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.